Pay in 4 interest-free payments of $5.85 Learn more
Ships within 48 hours · Estimated delivery Aug 9 - Aug 14
Retatrutide's Phase 2 trial data (Jastreboff et al., NEJM 2023) identified a side-effect profile broadly consistent with other incretin-based therapies: Gastrointestinal : Nausea, vomiting, diarrhoea, and constipation were the most commonly reported adverse effects, particularly during dose escalation
Each component is a well-characterized peptide with an established chemical identity and published molecular structure
We uphold the highest standards to ensure your comfort and safety
No published receptor binding constant or characterised minimum effective concentration anchors the dose, so dose decisions rest on preclinical envelopes. TB-4: cell migration What it is TB-4 is a naturally occurring 43-amino-acid peptide involved in cell movement and tissue repair
Frequency Based on Severity : Mild deficiency : Injections may be needed every 3-6 months
This compound was sterilized and lyophilized to meet the regulatory requirements of preclinical studies
